Zobrazeno 1 - 10
of 70
pro vyhledávání: '"X. Tsiafaki"'
Autor:
D. Melemeni, Christos Damaskos, X. Tsiafaki, N. Trakas, Nikolaos Garmpis, K. Mantzouranis, V.E. Georgakopoulou, P. Sklapani, Aikaterini Aravantinou, Anna Garmpi, S. Chlapoutakis, Aikaterini Gkoufa
Publikováno v:
Respiratory Medicine and Research. 79:100815
Background Extramedullary hematopoiesis is defined as hematopoiesis occurring outside of the bone marrow. It usually compensates insufficient bone marrow function or ineffective erythropoiesis and is observed mostly in hematological disorders. Most c
Autor:
Vassilis Georgoulias, Athanasios Kotsakis, Dora Hatzidaki, Anna Agelidou, Vassilios Chandrinos, X. Tsiafaki, Aris Polyzos, Nikolaos Kentepozidis, Lambros Vamvakas, Athanasios Karampeazis, Charalambos Christophyllakis
Publikováno v:
Journal of Geriatric Oncology. 8:23-30
Objectives To compare first-line treatment with docetaxel plus gemcitabine (DG) versus gemcitabine (G) in elderly patients with advanced/metastatic non-small-cell lung cancer (NSCLC). Patients and Methods Chemotherapy-naive patients with inoperable s
Publikováno v:
Chest. 155:A380
Autor:
Vassilis Georgoulias, M. Agelidou, Ioannis Boukovinas, Nikolaos Androulakis, A. Agelidou, Charalambos Christophyllakis, Stelios Giassas, X. Tsiafaki, Vassilis Chandrinos, Athanasios G. Pallis, Georgia Pavlakou, Aris Polyzos, Nikolaos Kentepozidis, Lambros Lamvakas, Stelios Kakolyris, Sophia Agelaki
Publikováno v:
Journal of Thoracic Oncology. 3:505-510
IntroductionThirty to 40% of patients with non-small cell lung cancer (NSCLC) are older than 70 years and rarely are enrolled in clinical trials. Moreover, in clinical practice, >75% of patients older than 65 years with metastatic NSCLC never receive
Autor:
George Blazoyiannakis, John Souglakos, X. Tsiafaki, E. Papadakis, Ageliki Rapti, Sophia Agelaki, Helen Bania, Nikos Androulakis, Charalambos Kouroussis, Vassilis Georgoulias, Kostas Kalbakis
Publikováno v:
Lung Cancer. 34:77-80
Objective: A phase II study was conducted to evaluate the efficacy and toxicity of vinorelbine–carboplatin (VNB–C) combination as a salvage treatment in patients with advanced non-small cell lung cancer (NSCLC) progressing after or failing previo
Autor:
George Samonis, Th. Giannakakis, M. Veslemes, E. Papadakis, J. Vlachonikolis, V. Georgoulias, D. Mavroudis, Th. Grigoratou, S. Kakolyris, Ch. Kouroussis, Ageliki Rapti, Ph. Palamidas, A. Alexopoulos, X. Tsiafaki
Publikováno v:
Lung Cancer. 34:47-51
The study compares docetaxel plus cisplatin (DC) and docetaxel plus gemcitabine (DG) regimens for the treatment of advanced non-small cell lung cancer (NSCLC). Patients were randomized to receive either the DC or the DG combination. They were stratif
Autor:
E. Papadakis, A. Alexopoulos, X. Tsiafaki, V. Georgoulias, M. Veslemes, Ph. Palamidas, Ageliki Rapti, I Vlachonikolis
Publikováno v:
The Lancet. 357:1478-1484
Summary Background Docetaxel in combination with cisplatin or gemcitabine are active chemotherapy reigimes against non-small-cell lung cancer. We compared the efficacy and safety of a combination of cisplatin and docetaxel (group 1) with that of gemc
Autor:
X. Tsiafaki, E. Papadakis, Sophia Agelaki, Ageliki Rapti, Nikos Androulakis, C. Kalofonos, N. Vardakis, E. Bania, Ch. Kouroussis, V. Georgoulias, E. Sarra, M. Toubis, Kyriakos Chainis, S. Kakolyris
Publikováno v:
Lung Cancer. 32:179-187
Background: Docetaxel in combination with gemcitabine is an active front-line chemotherapy regimen against non-small cell lung cancer (NSCLC) with acceptable toxicity. A multicenter phase II study was conducted in order to determine the toxicity and
Autor:
D. Mavroudis, E. Papadakis, M. Veslemes, X. Tsiafaki, J. Stavrakakis, C. Kouroussis, S. Kakolyris, E. Bania, J. Jordanoglou, M. Agelidou, J. Vlachonicolis, V. Georgoulias
Publikováno v:
Annals of Oncology. 12:463-470
Background: Previous phase I-II studies have shown that the combination of paclitaxel-cisplatin etoposide (TEP) is very active and well tolerated in patients with small-cell lung cancer (SCLC). In order to compare the TEP combination to cisplatin eto
Autor:
E. Sarra, Sophia Agelaki, X. Tsiafaki, E. Papadakis, Nikos Androulakis, Kostas Kalbakis, Vassilis Georgoulias, Helen Bania, Charalambos Kouroussis, George Blazoyiannakis, Adriani Harpidou, John Souglakos, Ageliki Rapti
Publikováno v:
Oncology. 60:235-241
Two parallel phase II trials were conducted in order to evaluate the efficacy and toxicity of vinorelbine-ifosfamide (VNB-IFX) and vinorelbine-carboplatin (VNB-C) combinations as salvage treatment in patients with advanced non-small cell lung cancer